REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/13/2026
Back to search
Official data from USPTO
EXSERA BIOLABS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EXSERA BIOLABS
ST13
US500000087088353Class
42, 44
Filing
87088353
Registration
5224578
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
06/14/2026
Trademark type
Word
Nice classes
42, 44
Filing date
06/29/2016
Registration date
06/13/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/06/2023
Last transaction
06/14/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/01/2016
First use in commerce
07/28/2016
Drawing code
4
Owner type
99
Owner location
Denver, CO, US
Examiner
KHAN, ASMAT A
Law office
M50
Current location
TMO LAW OFFICE 114
Holders and representatives
Holders
The Regents of the University of Colorado, a body corporate
Representatives
The Regents of the University of Colorado, a body
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical drug development services; Research and development in the field of reagentassaybiomarker and clinical target development
Class 44
Medical testing for diagnostic or treatment purposes in the field of rheumatologyautoimmunitycomplement and esoteric biomarkers
Publications
History of USPTO decisions and trademark events.
27 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/07/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/06/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/06/2023
E815
TEAS SECTION 8 & 15 RECEIVED
06/08/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/13/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/12/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/11/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/26/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/24/2017
IUAF
USE AMENDMENT FILED
03/14/2017
EISU
TEAS STATEMENT OF USE RECEIVED
03/14/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/24/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/29/2016
PUBO
PUBLISHED FOR OPPOSITION
11/29/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/09/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/27/2016
ALIE
ASSIGNED TO LIE
10/23/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/11/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
10/11/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/11/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
10/11/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/11/2016
DOCK
ASSIGNED TO EXAMINER
10/06/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/05/2016
NWAP
NEW APPLICATION ENTERED
07/02/2016
Continuous trademark protection
Get notified about every new filing that threatens EXSERA BIOLABS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.